These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 32001325)

  • 1. FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis.
    Panzitt K; Jungwirth E; Krones E; Lee JM; Pollheimer M; Thallinger GG; Kolb-Lenz D; Xiao R; Thorell A; Trauner M; Fickert P; Marschall HU; Moore DD; Wagner M
    J Hepatol; 2020 Jun; 72(6):1122-1131. PubMed ID: 32001325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Bordoni M; Roselli R; Di Giorgio C; Baldoni M; Ricci P; Monti MC; Morretta E; Zampella A; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158733. PubMed ID: 32371093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
    Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
    JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid.
    de Haan LR; Verheij J; van Golen RF; Horneffer-van der Sluis V; Lewis MR; Beuers UHW; van Gulik TM; Olde Damink SWM; Schaap FG; Heger M; Olthof PB
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33578971
    [No Abstract]   [Full Text] [Related]  

  • 5. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
    Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
    Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 by the farnesoid X receptor and bile acids.
    Erichsen TJ; Aehlen A; Ehmer U; Kalthoff S; Manns MP; Strassburg CP
    J Hepatol; 2010 Apr; 52(4):570-8. PubMed ID: 20189675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
    Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of autophagy by bile acids and in cholestasis - CholestoPHAGY or CholeSTOPagy.
    Panzitt K; Fickert P; Wagner M
    Biochim Biophys Acta Mol Basis Dis; 2021 Feb; 1867(2):166017. PubMed ID: 33242590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.
    Liu T; Yang H; Fan W; Tu J; Li TWH; Wang J; Shen H; Yang J; Xiong T; Steggerda J; Liu Z; Noureddin M; Maldonado SS; Annamalai A; Seki E; Mato JM; Lu SC
    Gastroenterology; 2018 Aug; 155(2):557-571.e14. PubMed ID: 29733835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
    Xiong X; Ren Y; Cui Y; Li R; Wang C; Zhang Y
    Biomed Pharmacother; 2017 Dec; 96():1292-1298. PubMed ID: 29174575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion.
    Lew JL; Zhao A; Yu J; Huang L; De Pedro N; Peláez F; Wright SD; Cui J
    J Biol Chem; 2004 Mar; 279(10):8856-61. PubMed ID: 14684751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nerve growth factor induced farnesoid X receptor upregulation modulates autophagy flux and protects hepatocytes in cholestatic livers.
    Tsai MS; Lee HM; Huang SC; Sun CK; Chiu TC; Chen PH; Lin YC; Hung TM; Lee PH; Kao YH
    Arch Biochem Biophys; 2020 Mar; 682():108281. PubMed ID: 32001246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hesperidin alleviates cholestasis via activation of the farnesoid X receptor in vitro and in vivo.
    Zhang G; Sun X; Wen Y; Shi A; Zhang J; Wei Y; Wu X
    Eur J Pharmacol; 2020 Oct; 885():173498. PubMed ID: 32841642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational discovery and experimental verification of farnesoid X receptor agonist auraptene to protect against cholestatic liver injury.
    Gao X; Fu T; Wang C; Ning C; Kong Y; Liu Z; Sun H; Ma X; Liu K; Meng Q
    Biochem Pharmacol; 2017 Dec; 146():127-138. PubMed ID: 28987596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
    J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor.
    Narayanan AK; Surendran S; Balakrishnan D; Gopalakrishnan U; Malick S; Valsan A; Philips CA; Watson CJE
    Curr Rev Clin Exp Pharmacol; 2024; 19(3):225-233. PubMed ID: 38708917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis.
    Meng Q; Chen XL; Wang CY; Liu Q; Sun HJ; Sun PY; Huo XK; Liu ZH; Yao JH; Liu KX
    Toxicol Appl Pharmacol; 2015 Mar; 283(3):178-86. PubMed ID: 25655198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist.
    Fujita K; Iguchi Y; Une M; Watanabe S
    Lipids; 2017 Apr; 52(4):335-344. PubMed ID: 28315136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.